Home Cytoskeletal Signaling Integrin

Integrin

Other Cytoskeletal Signaling Related Inhibitors

HSP Kinesin Microtubule Associated PAK Dynamin MLCK TACC3 Gap-Junction Actin Cardiac Myosin

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S7540 SB273005 SB273005 is a potent integrin inhibitor with Ki of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.
EMBO J, 2025, 10.1038/s44318-025-00565-3
bioRxiv, 2025, 2025.04.25.650475
Cancer Lett, 2024, 582:216597
Verified customer review of SB273005
S7077 Cilengitide trifluoroacetate Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
J Neuroinflammation, 2025, 22(1):168
Int J Mol Sci, 2025, 26(6)2465
Microbiol Spectr, 2025, 13(2):e0222124
Verified customer review of Cilengitide trifluoroacetate
S6387 Cilengitide (EMD 121974) Cilengitide (EMD 121974, EMD-12192, EMD-85189, NSC-​707544) is a potent and selective inhibitor of the integrins ανβ3 and ανβ5 with IC50 of 4 and 79 nM, respectively.
Nat Commun, 2025, 16(1):2254
NPJ Regen Med, 2024, 9(1):4
World J Gastroenterol, 2024, 30(7):728-741
S8008 RGD peptide (Arg-Gly-Asp) RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.
Adv Sci (Weinh), 2025, 12(18):e2417447
J Sport Health Sci, 2024, S2095-2546(24)00124-8
iScience, 2024, 27(3):109119
Verified customer review of RGD peptide (Arg-Gly-Asp)
S8454 ATN-161 ATN-161 is a novel small peptide antagonist of integrin α5β1. It binds to several integrins, including α5β1 and αvβ3, that play a role in angiogenesis and tumor progression.
Nat Commun, 2025, 16(1):6531
Nat Commun, 2025, 16(1):9183
Regen Biomater, 2025, 12:rbaf099
S7834 Cyclo(-RGDfK) TFA Cyclo(-RGDfK) TFA is the salt product of Cyclo(-RGDfK) and trifluoroacetic acid (TFA). The addition of TFA enhances stability and biocompatibility. This compound effectively targets tumor microvessels and cancer cells by specifically binding to the cell surface Integrin αvβ3.
Pharmaceuticals (Basel), 2025, 18(4)549
In Vitro Cell Dev Biol Anim, 2025, 10.1007/s11626-025-01101-7
Sci Adv, 2024, 10(43):eadp4726
S7844 Cyclo(RGDyK) TFA Cyclo(RGDyK) TFA is a salt formed by the combination of Cyclo(RGDyK) and trifluoroacetate (TFA). It is an effective and selective Integrin αvβ3 inhibitor with a low IC50 value (e.g., 20 nM). This compound is of great significance in the treatment of cardiovascular diseases, osteoporosis, inflammation and tumors.
J Clin Invest, 2024, e175147
JBMR Plus, 2024, 8(7):ziae066
Cell Commun Signal, 2023, 10.1186/s12964-022-01027-7
Verified customer review of Cyclo(RGDyK) TFA
S8306 Leukadherin-1 Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1 (an agonist for the complement receptor 3 (CD11b/CD18)).
International Immunopharmacology, 2023, Volume 118
Int Immunopharmacol, 2023, 118:110024
Front Immunol, 2022, 13:919444
S2885 A-205804 A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively.
Cell Biol Toxicol, 2024, 40(1):90
Stem Cell Res Ther, 2022, 13(1):218
Am J Rhinol Allergy, 2022, 19458924221086061
Verified customer review of A-205804
S3714 Lifitegrast Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.
Med Oncol, 2024, 41(8):188
World J Gastroenterol, 2023, 29(20):3103-3118
Med Chem Res, 2022, 31(4):555-579

Signaling Pathway Map